| Abstract: | BackgroundTo clarify and update the prognostic assessment for heterogeneous population of patients with breast cancer and spine metastases (SpM), using molecular markers.MethodsThe patient data used in this study was obtained from a French national multi-center database of patients treated for breast cancer with SpM between 2014 and 2017. 556 SpM cases were diagnosed.ResultsMedian overall survival (OS) time for all patients following the SpM event was 43.9 months. First, we confirmed 3 previously known significant prognostic factors for survival of patients with SpM: young age HR: 2.019, 95% CI 1.343–3.037; p = 0.001], good WHO status Status 0 HR: 2.823, 95% CI 1.231–3.345; p < 0.0001] or Status 1 HR: 1.956, 95% CI 0.768–2.874; p = 0.001] and no-ambulatory neurological status: Frankel A-C HR: 0.438, 95% CI 0.248–0.772; p = 0.004]. Secondly, we determined the effect of gene mutations on survival in patients with SpM, and we identified that HER2+ cancer subtype HR: 1.567, 95% CI 0.946–2.557; p = 0.008] was an independent predictor of longer survival, whereas basal cancer subtype HR: 0.496, 95% CI 0.353–0.699; p < 0.0001] was associated with a poorer prognosis. Other factors including the number of SpM, surgery, extraspinal metastases, synchrone metastases, metastasis-free survival, and SpM recurrence were not identified as prognostically relevant to survival.ConclusionSurvival and our ability to estimate it in breast cancer patients with SpM has improved significantly. Therefore, SpM prognostic scoring algorithms should be updated and incorporate genotypic data on subtypes to make treatment more adaptive. |
